The therapeutic application of Сибазон (Diazepam) is defined by its ability to provide supportive relief across domains marked by symptoms related to heightened physiological activity.

The medication is commonly used to provide short-term symptomatic support for severe anxiety and generalized tension, the management of acute alcohol withdrawal, relief from skeletal muscle spasm and spasticity, and assisting with managing acute convulsive crises. It is applied in clinical settings that involve acute or unstable symptom patterns, helping to address symptom clusters that create noticeable physiological strain.

As a supportive measure, the therapy helps maintain a sense of stability when symptoms are more noticeable, assisting with functional stability. The overall goal is to ease the impact of disruptive manifestations.

Therapeutic Focus (Summary)
Core Symptom Areas	Acute Distress and Involuntary Spasm
Symptom Characteristic	Heightened Physiological Activity
Benefit	Contributes to easing the overall symptom load

Regulatory References

1. National Institutes of Health overview

Who can and cannot use Сибазон?

The eligibility for Сибазон (Diazepam) is strictly defined by regulatory documents, listing populations that are prohibited from use and those requiring conditional precautions. The medicine is generally permitted for adults and for children aged 6 months and older (oral forms).

---

Contraindications (Absolute Exclusion)

The medicine must not be used by patients with: Known hypersensitivity to Diazepam; Myasthenia Gravis; Severe Hepatic Insufficiency or Severe Respiratory Insufficiency; Sleep Apnea Syndrome; or Acute Narrow-Angle Glaucoma. The oral tablet form is also contraindicated in children under 6 months of age.

---

Population-Specific Restrictions

• Older Adults: Use requires lower doses due to decreased clearance; long-acting benzodiazepines are generally not recommended due to increased fall risk.
• Conditional Use: Patients with chronic respiratory insufficiency or mild to moderate hepatic impairment require explicit caution.
• Comorbidities: It is not recommended as sole therapy for patients with psychosis or anxiety associated with depression, and use requires extreme caution in individuals with a history of alcohol or drug dependence.
• Reproductive Status: Use during pregnancy is conditional upon the clinical situation warranting the risk to the fetus. It is not recommended while breastfeeding.

Interactions with other medicines and products

The official regulatory documentation for Сибазон (Diazepam) details multiple clinically significant interaction patterns, primarily categorized as pharmacodynamic potentiation and pharmacokinetic modifications.

A major safety restriction applies to co-administration with Opioids. This combination carries an explicit regulatory Boxed Warning due to the risk of profound sedation, respiratory depression, coma, and death, necessitating limits on dosage and duration. Additive central nervous system (CNS) depression is also documented with alcohol and other CNS-depressant medicinal products, including barbiturates, antipsychotics, and muscle relaxants.

Pharmacokinetic and Exposure Modifications

The product's elimination is subject to pharmacokinetic interactions involving the hepatic enzymes CYP2C19 and CYP3A4. Substances classified as enzyme inhibitors (e.g., certain antiulcer agents or antifungals) are documented to decrease the rate of clearance, which may lead to increased plasma concentrations and prolonged exposure. Conversely, enzyme inducers (e.g., certain anticonvulsants) may increase clearance, potentially reducing efficacy. Additionally, Valproic acid is documented to significantly increase the free fraction of the drug through both protein binding displacement and metabolic inhibition.

Procedural and Population Notes

Caution regarding interaction potential is also advised in patients with impaired hepatic function due to the liver’s role in metabolism, and in patients with compromised kidney function due to the risk of metabolite accumulation. For the injection solution, a procedural restriction mandates that it must not be mixed or diluted with other solutions in the same syringe or infusion container.

Сибазон (Sibazon) is a brand name for the drug diazepam, a benzodiazepine. It works primarily by modulating the GABA-A receptor complex in the central nervous system (CNS), which is the principal mediator of inhibitory neurotransmission in the brain.

---

Positive Allosteric Modulation of GABA-A Receptors

This domain covers the drug's core molecular target: the GABA-A receptor. Сибазон acts as a positive allosteric modulator, binding to a specific site on the receptor complex (at the interface of alpha and gamma subunits) distinct from the site where the inhibitory neurotransmitter GABA binds. This engagement enhances the effect of endogenous GABA, leading to an increased frequency of chloride ion channel opening and subsequent hyperpolarization of the neuron. This binding contributes to a reduction in the excitability of targeted neuronal circuits.

---

CNS Inhibitory Signaling Potentiation

This domain outlines the immediate cellular and systemic consequence of GABA-A receptor modulation. By increasing the influx of chloride ions into the postsynaptic neuron, the drug makes the neuron less excitable and more resistant to activation by excitatory neurotransmitters. This potentiation of inhibitory pathways across the central nervous system modulates signaling pathways characterized by elevated neurotransmitter release. The net effect results in a quantifiable change in cellular membrane potential and subsequent neuronal firing rate.

Сибазон (Diazepam) is administered through several official routes depending on the clinical context. Oral administration, via tablets, is the primary route for routine use, with typical adult dosing ranging from 2 mg to 10 mg two to four times daily. The total daily intake for severe conditions should not exceed 30 mg in divided doses.

Conversely, acute situations require parenteral administration; the solution for injection is approved for both intravenous (IV) and intramuscular (IM) use. The IV route is often preferred for acute needs, and official instructions mandate a slow injection rate, not exceeding 5 mg per minute, and prohibit mixing the solution with other injectables.

Dosing is always subject to official population-specific instructions. For older or debilitated adults, the starting dose is officially reduced to approximately half the standard adult dose, often 2 mg to 2.5 mg once or twice daily. Administration conditions specify that oral absorption is delayed when the medication is taken with a moderate fat meal.

The duration of use is strictly governed: treatment for anxiety must be for the shortest possible time, generally not exceeding 8 to 12 weeks, inclusive of a mandatory, gradual tapering period required to discontinue therapy. Rectal and specialized intranasal forms are also approved for intermittent use in acute, time-limited scenarios, not for long-term maintenance.

Research evidence / Overview of studies for Сибазон

Evidence for Use in Acute Neurological Conditions (Seizures)

Сибазон (Diazepam) was studied for use in acute neurological conditions, specifically during prolonged seizures known as status epilepticus, and the research includes Randomized Controlled Trials (RCTs) and systematic reviews. This body of research was applied in studies that monitored outcomes describing episodic or acute changes during neurological events. Researchers focused on monitored outcomes describing the time to reach seizure cessation and the rate of recurrence within the immediate hours after the medicine was administered. These studies included populations of both adults and children in settings with heightened symptom activity, such as emergency care.

What remains uncertain is how this short-term intervention fits into long-term care. The existing evidence provides context but not individual predictions, and research provides limited insight into the need for subsequent long-term seizure management or how the findings translate to understanding symptom patterns during sustained periods.

Evidence for Use in Acute Anxiety and Withdrawal Management

Сибазон was studied for two distinct indications, where research explored how symptoms change over time: severe, acute anxiety and acute alcohol withdrawal syndrome.

For severe acute anxiety, studies include short-term RCTs that measured changes using clinical rating scales. These trials examined symptom intensity or variability in adult populations during periods of increased symptom activity. Studies report how symptoms evolved in the observed populations, and research suggests patterns related to short-term changes. Findings indicate that studies reported measurements of symptom variability during the initial weeks of the study period.

For acute alcohol withdrawal, research examined temporary physiological imbalance, specifically focusing on outcomes related to systemic or functional imbalance, such as outcomes describing episodic or acute changes related to severe withdrawal manifestations. Studies monitored scores on standardized withdrawal scales during short, defined time intervals.

Limitations and Gaps in the Current Research

While many years of use have contributed to the broader evidence landscape, several research limitations and gaps have been noted. Follow-up durations were limited across many indications, especially for anxiety and muscle spasm, meaning long-term effects are not fully established. Data for certain groups remain insufficient, including pregnant or breastfeeding populations, and individuals with specific comorbidities. The research focuses almost entirely on studies conducted during periods of increased symptom activity and does not determine whether an individual will respond similarly when using the drug for long-term purposes.

Key Studies & References

1. Lorazepam v. diazepam for pediatric status epilepticus
2. Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials
3. Treatment, discontinuation, and psychomotor effects of diazepam in women with generalized anxiety disorder

Common questions about Сибазон (FAQ)

Q: Is Sibazon officially approved for the treatment of anxiety?

Regulatory documents classify Sibazon (Diazepam) as an anxiolytic, which is a substance used to alleviate anxiety.

It is included in official product information for the treatment of severe, acute anxiety.

Q: Does this medicine cause dependence? How likely is it?

Official documentation describes the potential risk of developing physical and psychological dependence, as well as misuse and abuse.

The risk of dependence is described as increasing with the dosage and the duration of use.

Q: How long can Sibazon be taken without a break, according to official guidance?

Official documents stipulate that treatment for anxiety should be for the shortest possible time to minimize risk.

This period is generally limited to a maximum of 8 to 12 weeks, a timeframe which includes the necessary gradual dose reduction (tapering) period.

Q: Is it true that suddenly stopping Sibazon can be dangerous?

Official safety information indicates that abrupt cessation, particularly following long-term or high-dose use, can lead to a withdrawal syndrome.

Withdrawal symptoms can be serious and potentially dangerous.

Q: Is it necessary to gradually decrease the dose of Sibazon before stopping?

Official regulations describe the necessity of a gradual dose reduction, known as tapering, to successfully discontinue therapy.

This measured process is necessary to help minimize the risks associated with cessation.

Q: Can Sibazon interact with herbal supplements or dietary supplements?

Official sources warn of interactions with substances that cause central nervous system (CNS) depression.

This warning includes certain herbal and dietary supplements that have sedative properties.

Q: Sibazon and pregnancy: what do official sources say?

Use during pregnancy is not recommended, particularly in the first trimester, due to a possible increased risk of congenital malformations.

Application is conditional and is only considered if the clinical situation fully warrants the potential risk to the fetus.

Q: How soon after taking Sibazon can I feel the effect?

According to official clinical pharmacology information, after swallowing the oral tablets, effects may begin to appear within 15 to 60 minutes.

Q: How long does the effect of one Sibazon tablet last?

The noticeable physiological effect of a single dose can typically last between 4 to 6 hours.

It is important to note that active metabolites of the drug can remain detectable in the body for a much longer period.

Q: Can I take Sibazon if I have liver problems?

The drug is strictly contraindicated in cases of severe hepatic (liver) insufficiency due to the risk of encephalopathy.

For patients with mild or moderate liver function impairments, caution and careful monitoring are officially advised.

Q: Can I take Sibazon if I have kidney problems?

Official documents advise caution when administered to patients with impaired kidney function due to the risk of metabolite accumulation.

Q: What popular over-the-counter (OTC) medicines can Sibazon interact badly with?

The risk of central nervous system (CNS) depression is heightened when Sibazon is taken alongside other CNS depressants.

This includes certain popular over-the-counter cold, flu, and sleep aids that contain sedating ingredients such as antihistamines.

Q: Are there age restrictions in official documents for taking Sibazon?

Official documents state that the drug is generally permitted for adults and for children aged 6 months and older (oral forms).

In older people, the recommended starting dose is lower due to increased sensitivity to the drug's effects.

Q: Why does Sibazon have 'prescription only' status?

Sibazon (Diazepam) is classified internationally as a Schedule IV controlled substance.

This classification is due to its confirmed potential for abuse, the development of dependence, and misuse, which necessitates strict regulatory control over its dispensing.

Q: Is it necessary to take Sibazon strictly before or after a meal?

Official information regarding the drug’s pharmacokinetics indicates that taking the oral forms with a moderate fat meal may delay the rate at which it is absorbed into the bloodstream.

Q: Why does Sibazon sometimes cause unusual or opposite reactions, such as excitement?

Official documentation describes the possibility of experiencing so-called paradoxical reactions as a potential adverse effect.

These reactions can include excitement, agitation, or aggression, but the specific underlying reason for their occurrence is not detailed in the product documents.

Q: What research has been conducted on the long-term use of Sibazon?

Research studies for many of the drug's indications, including anxiety and muscle spasms, have had limited follow-up durations.

As a result, official summaries indicate that the long-term effects of the drug are not fully established by current research.

Q: Is there information about Sibazon's influence on blood pressure?

Official safety data confirms that hypotension (low blood pressure) is documented among the registered adverse effects.

Q: Can long-term use of Sibazon weaken its effect (tolerance)?

Official information confirms that with the prolonged and regular use of benzodiazepines, there is a risk of developing tolerance.

Tolerance is the body's adaptation that can lead to the drug’s intended action diminishing over time.

Q: Can Sibazon be used to treat insomnia?

Sibazon (Diazepam) may be used for the short-term treatment of insomnia related to anxiety due to its sedative properties.

Specifically, it is used for sleep disturbances that are related to acute or severe anxiety.

Q: Why is muscle weakness sometimes felt when taking Sibazon?

Sibazon is classified as a central muscle relaxant, which inherently affects muscle tone.

Official adverse effects like ataxia (lack of coordination) and fatigue are documented and linked to the drug's action on the muscular system.

Q: What dose strengths is Sibazon available in?

Sibazon (Diazepam) for oral administration is commonly manufactured as tablets in standard dose strengths.

These typically include tablets of 2 mg, 5 mg, and 10 mg.

Storage and Disposal Conditions for Сибазон (Diazepam)

Сибазон must be stored according to official regulatory specifications to maintain product integrity and ensure safety.

Storage Requirements

Condition	Regulatory Requirement
Temperature	Store at Controlled Room Temperature (20 C to 25 C).
Protection	Keep protected from light, moisture, and do not freeze the product.
Container	Store in the original container and keep it tightly closed.
Child Safety	Due to its status as a Controlled Substance, keep the medication out of the sight and reach of children.

Disposal Instructions

Unused or expired Сибазон must be disposed of in accordance with all applicable local regulations for Controlled Substances. Disposal should utilize an official drug take-back program where available, and the product must not be disposed of via wastewater (i.e., flushed down the toilet or poured down the sink).